Alirocumab

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.

Journal: Journal of the American Heart Association

Published: April 07, 2026

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Journal: Future oncology (London, England)

Published: April 06, 2026

Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.

Journal: Expert opinion on pharmacotherapy

Published: March 05, 2026

Comparison of Atheroma Burden Changes Using Conventional vs. End-Diastolic Intravascular Ultrasound Segmentation　- Post Hoc Analysis of the PACMAN-AMI Study.

Journal: Circulation journal : official journal of the Japanese Circulation Society

Published: March 04, 2026

Therapeutic Effects of PCSK9 Inhibitors on Lp(a)-Associated Atherosclerosis: Evidence and Perspectives.

Journal: Journal of cardiovascular pharmacology

Published: February 12, 2026

Integrative Proteomic and Lipidomic Analysis of Post-Myocardial Infarction Patients Treated With PCSK9 Antibodies and Statins.

Journal: Circulation. Genomic and precision medicine

Published: February 10, 2026

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Journal: Journal of clinical medicine research

Published: January 30, 2026

PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway.

Journal: International journal of molecular sciences

Published: January 18, 2026

Alirocumab Attenuated Plaque Inflammation and PCSK9-Induced Proinflammatory Signalling in M1 Macrophages Independently of Lipid Lowering.

Journal: Biomolecules

Published: January 09, 2026

Correction.

Journal: The Medical letter on drugs and therapeutics

Published: January 08, 2026

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study.

Journal: Lipids in health and disease

Published: January 07, 2026

The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.

Journal: Microvascular research

Published: December 31, 2025

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.

Early PCSK9 Inhibitor Use Correlates With Improved Outcomes in Patients With Acute Stroke Receiving Endovascular Therapy.

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.

Pharmacological management of elevated LDL in patients with hypercholesterolaemia and mixed dyslipidaemia.

Comparison of Atheroma Burden Changes Using Conventional vs. End-Diastolic Intravascular Ultrasound Segmentation - Post Hoc Analysis of the PACMAN-AMI Study.

Comparison of Atheroma Burden Changes Using Conventional vs. End-Diastolic Intravascular Ultrasound Segmentation - Post Hoc Analysis of the PACMAN-AMI Study.

Therapeutic Effects of PCSK9 Inhibitors on Lp(a)-Associated Atherosclerosis: Evidence and Perspectives.

Therapeutic Effects of PCSK9 Inhibitors on Lp(a)-Associated Atherosclerosis: Evidence and Perspectives.

Integrative Proteomic and Lipidomic Analysis of Post-Myocardial Infarction Patients Treated With PCSK9 Antibodies and Statins.

Integrative Proteomic and Lipidomic Analysis of Post-Myocardial Infarction Patients Treated With PCSK9 Antibodies and Statins.

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

Novel Approaches to Lipid Management: Beyond Statins and PCSK9 Inhibitors.

PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway.

PCSK9 Inhibitor Alirocumab Improves Diabetic Cardiomyopathy Through the ERK/p38 MAPK Signaling Pathway.

Alirocumab Attenuated Plaque Inflammation and PCSK9-Induced Proinflammatory Signalling in M1 Macrophages Independently of Lipid Lowering.

Alirocumab Attenuated Plaque Inflammation and PCSK9-Induced Proinflammatory Signalling in M1 Macrophages Independently of Lipid Lowering.

Correction.

Correction.

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study.

Real-world effectiveness and cardiovascular outcomes of PCSK9 inhibitor therapy: a prospective registry study.

The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.

The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.

Comparison of Atheroma Burden Changes Using Conventional vs. End-Diastolic Intravascular Ultrasound Segmentation　- Post Hoc Analysis of the PACMAN-AMI Study.

Comparison of Atheroma Burden Changes Using Conventional vs. End-Diastolic Intravascular Ultrasound Segmentation　- Post Hoc Analysis of the PACMAN-AMI Study.